858-692-3573 info@denovicontx.com

No Guesses, Just Successes by

Computational Design

Denovicon’s mission is to bring better quality drugs to market faster and more affordably than existing methods. To do so, we’ve created a drug discovery platform that’s powered by AI, machine learning, generative therapeutic design, and physics-based approaches to achieve the best results. The platform effectively and swiftly triages trillions of molecules to identify high-quality leads (not simply hits) and transform them into optimized clinical candidates. In this way, the platform streamlines the overall drug discovery process leading to savings in time and money, while achieving higher rates of clinical success – and down the line, to better patient outcomes. 

Denovicon Reports Discovery of DNT-1569: A Highly Selective Small Molecule PARP7 Inhibitor for Immuno-Oncology

A small molecule oral immunomodulator with first-in-class selectivity over PARP1 and PARP2 — computationally designed in less than a year San Diego, CA — Denovicon Therapeutics, Inc. today announces the discovery of DNT-1569, a small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) designed as a potential oral immunomodulatory therapy for solid tumors. To the best […]

Read more

Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs

A druglikeness-first approach that searches trillion-molecule spaces to deliver lead-ready compounds The Drug Discovery Bottleneck After nearly 25 years in drug discovery, I’ve watched the same pattern repeat. Programs identify modest hits, then spend five to seven years attempting to optimize toward a clinical candidate—most of which never materialize. The failures are rarely due to […]

Read more

Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator

Denovicon Therapeutics has been renewed for a three-year membership in the 3DEXPERIENCE Lab accelerator, the global innovation program of Dassault Systèmes. Denovicon remains the only biotechnology company in the accelerator’s portfolio, underscoring the program’s confidence in our AI-driven approach to small-molecule drug discovery. Since our initial acceptance in October 2024, we have deepened our collaboration […]

Read more

Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network

San Diego, CA, October 1, 2025—Denovicon Therapeutics, an AI-driven drug discovery company based in San Diego, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston […]

Read more

Re-Inventing Drug Discovery

Denovicon uses an innovative combination of machine learning and physics-based modeling to streamline the development of small molecule therapeutics, dramatically reducing R&D timelines and improving clinical success. In a recent blog, Founder and CEO, Scott Bembenek reflects on the challenges of modern-day drug discovery and how Denovicon’s platform is leading the way in the computational/AI […]

Read more

Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator

On October 21, 2024, Denovicon Therapeutics was officially accepted into the 3DEXPERIENCE Lab accelerator. “I am very pleased to welcome Denovicon Therapeutics to drive this [revolution in drug discovery] effort and bring something really disruptive in this domain,” said Frederic Vacher, Head of Innovation at Dassault Systèmes. Jason Benedict of BIOVIA also expressed his enthusiasm, “We’ve […]

Read more

DRUG DISCOVERY CHEMISTRY CONFERENCE 2023

On April 12, 2023, Denovicon Therapeutics Founder & CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug Discovery – Part 2  in San Diego, CA.

Read more

Biovia User Group Meeting 2022

On October 11, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on ‘An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2022.

Read more

Denovicon Founder to Present at SLAS 2022

On February 8, 2022, Denovicon Therapeutics Founder & CEO, Scott Bembenek talked (along with BIOVIA’s Guy Oshiro) at SLAS 2022 about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.

Read more

BIO Partnering at JPM 2022

Denovicon was pleased to participate in BIO Partnering at JPM 2022. If you’re interested in learning more about our AI–physics-driven drug discovery platform and current molecular assets, feel free to reach out.

Read more

Biovia User Group Meeting 2021

On September 14, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, presented on Denovicon’s ‘AI–Molecular Modeling Platform for Enhanced Small-Molecule Drug Discovery’ at the Biovia User Group Meeting 2021.

Read more

AI in Drug Discovery 2021

On March 15, 2021, Denovicon Therapeutics Founder & CEO, Scott Bembenek, talked on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design’ at the AI in Drug Discovery 2021.

Read more

Global Pharma R&D AI, Data Science and Informatics Summit 2020

On November 16, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, spoke at the Global Pharma R&D AI, Data Science and Informatics Summit (PRADI 2020) on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design.’

Read more

Lab of the Future Panel on Strategies for Accelerating Drug Discovery with AI

On November 5, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, took part in the Lab of the Future panel entitled ‘Strategies for Accelerating Drug Discovery with AI.’

Read more

Careers in Biotech Panel with Rady and UCSD PhD Students

On July 14, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, shared some of his experiences and insights from his scientific and entrepreneurial journeys (thus far) with Rady and UCSD students at Rady’s Careers in Biotech Panel.

Read more

Our Commitment to COVID-19

As part of Denovicon Therapeutics’ commitment to COVID-19, we tasked our novel molecular modeling-artificial intelligence (AI) hybrid computational platform to find potential therapies from over 13,000 FDA-approved drugs and clinical candidates. The molecular modeling tier focused on identifying potential inhibitors of the SARS-CoV-2 main protease (Mpro, 3CLpro), while the AI tier was not restricted to […]

Read more